Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29416267 | 1.00 | DGAT1 (0.30) | DGAT1 | |
| Methylamine SCHEMBL19466561 | 0.89 | DGAT1 (0.31) | DGAT1 | |
| SCHEMBL18976168 | 0.89 | DGAT1 (0.32) | DGAT1 | |
| SCHEMBL19466533 | 0.87 | DGAT1 (0.31) | DGAT1 | |
| SCHEMBL19466544 | 0.86 | TPH1 (0.30) | — | |
| SCHEMBL19466616 | 0.86 | TPH1 (0.33) | DGAT1 | |
| SCHEMBL19466601 | 0.86 | NPC1 (0.36) | — | |
| SCHEMBL19466563 | 0.85 | — | — | |
| SCHEMBL19466546 | 0.85 | DGAT1 (0.31) | DGAT1 | |
| SCHEMBL28491568 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4206205-B1 | PREPARATION METHOD FOR PYRROLOPYRIMIDINE COMPOUND | PRIMEGENE BEIJING CO LTD (CN) | 2026-03-04 | — | — | EP | disclosed |
| EP-4682149-A1 | POLYMORPH OF JAK TYROSINE KINASE INHIBITOR AND USE THEREOF | Prime Gene Therapeutics Co., Ltd. (CN) | 2026-01-21 | — | — | EP | disclosed |
| WO-2024193496-A1 | METHOD FOR PREPARING PYRROLOPYRIMIDINE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | 北京普祺医药科技股份有限公司 | 2024-09-26 | — | — | WO | disclosed |
| WO-2024193495-A1 | FUMARATE CRYSTAL FORM OF JAK TYROSINE KINASE INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 北京普祺医药科技股份有限公司 | 2024-09-26 | — | — | WO | disclosed |
| US-20230303578-A1 | PREPARATION METHOD FOR PYRROLOPYRIMIDINE COMPOUND | PRIMEGENE (BEIJING) CO., LTD. (CN) | 2023-09-28 | — | — | US | disclosed |
| US-20230303578-A1 | PREPARATION METHOD FOR PYRROLOPYRIMIDINE COMPOUND | PRIMEGENE (BEIJING) CO., LTD. (CN) | 2023-09-28 | — | — | US | disclosed |
| US-20230303578-A1 | PREPARATION METHOD FOR PYRROLOPYRIMIDINE COMPOUND | PRIMEGENE (BEIJING) CO., LTD. (CN) | 2023-09-28 | — | — | US | disclosed |
| EP-4206205-A1 | PREPARATION METHOD FOR PYRROLOPYRIMIDINE COMPOUND | Primegene (Beijing) Co., Ltd. (CN) | 2023-07-05 | — | — | EP | disclosed |
| EP-4206205-A1 | PREPARATION METHOD FOR PYRROLOPYRIMIDINE COMPOUND | Primegene (Beijing) Co., Ltd. (CN) | 2023-07-05 | — | — | EP | disclosed |
| WO-2022042577-A1 | PREPARATION METHOD FOR PYRROLOPYRIMIDINE COMPOUND | 北京普祺医药科技有限公司 | 2022-03-03 | — | — | WO | disclosed |
| US-10617692-B2 | Pyrrolopyrimidine comprising cyclopentyl substituent | CENTAURUS BIOPHARMA CO. (CN) | 2020-04-14 | — | — | US | disclosed |
| US-10561657-B2 | Pyrrolopyrimidine compound | Centaurus Biophrama Co., Ltd. (CN) | 2020-02-18 | — | — | US | disclosed |
| US-10561657-B2 | Pyrrolopyrimidine compound | Centaurus Biophrama Co., Ltd. (CN) | 2020-02-18 | — | — | US | disclosed |
| US-20190201403-A1 | PYRROLOPYRIMIDINE COMPOUND | LIANYUNGANG RUNZHONG PHARMACEUTICAL CO., LTD. (CN) | 2019-07-04 | — | — | US | disclosed |
| US-20190201403-A1 | PYRROLOPYRIMIDINE COMPOUND | LIANYUNGANG RUNZHONG PHARMACEUTICAL CO., LTD. (CN) | 2019-07-04 | — | — | US | disclosed |
| US-20190183899-A1 | PYRROLOPYRIMIDINE COMPRISING CYCLOPENTYL SUBSTITUENT | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2019-06-20 | — | — | US | disclosed |
| US-20190183899-A1 | PYRROLOPYRIMIDINE COMPRISING CYCLOPENTYL SUBSTITUENT | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2019-06-20 | — | — | US | disclosed |
| EP-3235819-A1 | PYRROLOPYRIMIDINE COMPOUND | Centaurus BioPharma Co., Ltd. (CN) | 2017-10-25 | — | — | EP | disclosed |
| EP-3235819-A1 | PYRROLOPYRIMIDINE COMPOUND | Centaurus BioPharma Co., Ltd. (CN) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016095805-A1 | PYRROLOPYRIMIDINE COMPOUND | 北京赛林泰医药技术有限公司 | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303578-A1 | PREPARATION METHOD FOR PYRROLOPYRIMIDINE COMPOUND | DPYD, RPLP2, DHPS | DGAT1 4030/4885 |
| US-10561657-B2 | Pyrrolopyrimidine compound | JAK2, JAK1, JAK3 | DGAT1 2691/4885 |
| US-20190201403-A1 | PYRROLOPYRIMIDINE COMPOUND | JAK2, JAK1, JAK3 | DGAT1 2691/4885 |
| US-10617692-B2 | Pyrrolopyrimidine comprising cyclopentyl substituent | JAK1, JAK2, JAK3 | DGAT1 2701/4885 |
| US-20190183899-A1 | PYRROLOPYRIMIDINE COMPRISING CYCLOPENTYL SUBSTITUENT | JAK1, JAK2, JAK3 | DGAT1 2701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.